Last reviewed · How we verify
NCT05247463: ATHENA-M
English Mammography Screening Outcomes by Age, Frequency and Test Threshold
trial testing Increase in upper age of eligibility for breast cancer screening from 64 to 70 in Breast Cancer in 10,000,000 participants. Status unknown.
30 December 2024
Quick facts
| Lead sponsor | University of Warwick |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000,000 |
| Start date | 1 January 2021 |
| Primary completion | 30 December 2024 |
| Estimated completion | 30 December 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Increase in upper age of eligibility for breast cancer screening from 64 to 70
- Screening round length
- Screening test threshold
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
University of Warwick
Who can join
Adults 47 to 73, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Breast cancer screening involves taking mammograms (x-rays) of women's breasts to search for signs of cancer. This study investigates the impact of test threshold, screening interval (frequency) and age of eligibility on intermediate outcomes, and health outcomes such as mortality and morbidity. This observational study links breast cancer screening, cancer registry and mortality registration data to answer these questions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05247463
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other University of Warwick trials
Trials by the same sponsor.
- NCT06334718 — Drone Delivered Defibrillators (The 3D Project). · completed
- NCT05402436 — Breast Screening Atypia and Subsequent Development of Cancer in England · completed
- NCT04977414 — Making Data Count Intervention Evaluation · NA · completed
- NCT05046197 — Evaluating the Integration of the Recommended Summary Plan for Emergency Care Treatment (ReSPECT) Into Primary Care · completed
- NCT04546854 — Influenza 2020/2021 · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05247463 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Warwick
- Last refreshed: 12 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05247463.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing